How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?  

I would give tafasatimab and Revlimid per the L-MIND study. I have been so impressed by this well tolerated immunotherapy regimen and the durability of responses. Literally, it looks competitive with car T cell therapy. Car, T cells would be an option, if the patient is very fit for their age and th...

Interesting case. In a similar case, I gave R-GCVP and achieved long remission. However, it depends on the time interval between prior regimens. If it was short, I’d probably do something like Len-Rituximab or Len-Tafa and justify the patient is transplant-ineligible.

If the goal is palliation then Tafasitamab + lenalidomide or bi-specifics. If the goal is cure and the patient is reasonably fit, then CAR T.

I would test his candidacy for CD19 CAR-T with Liso-Cel and if eligible, I would offer it to him. The PILOT  study (Sehgal et al., PMID 35839786) showed that the transplant-ineligible population (including those age 70 and above) achieved an ORR of 80% (54% CR) and those achieving CR have a lon...

It's a tough question, as there's no single standard of care approach here, especially because the patient-specific details really matter here. Options basically boil down to whether the patient is felt to benefit more from a cytotoxic approach or from a T-cell engaging approach. Approaches could be...